TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TmCD19-IL18’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TmCD19-IL18 overview

Gene therapy is under investigation for the treatment of non-Hodgkin lymphoma, diffuse large b-cell lymphoma, primary mediastinal (thymic) large b-cell lymphoma, anaplastic large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma and chronic lymphocytic leukemia (CLL). It is administered through intravenous route. The therapy constitutes of genetically manipulated autologous T cells which express human interleukin 18 (IL-18) and also express a chimeric antigen receptor (CAR) targeting cells expressing CD19.

Kite Pharma overview

Kite Pharma, a subsidiary of Gilead Sciences Inc, is a biopharmaceutical company that discovers and develops cancer immunotherapy products. Kite Pharma provides products like Chimeric Antigen Receptors(CAR), KTE-C19 DLBCL, PMBCL, TFL (ZUMA-1); Chemo Refractory Diffuse Large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), KTE-C19 MCL (ZUMA-2); Relapsed/Refractory Mantle Cell Lymphoma (MCL), KTE-C19 Adult and Pediatric ALL (ZUMA-3, ZUMA-4); Acute Lymphoblastic Leukemia (ALL), Axicabtagene ciloleucel; 2L+ high-risk follicular lymphoma, Axicabtagene ciloleucel; 1L high-risk large B-cell lymphoma, Axicabtagene ciloleucel; 2L large B-cell lymphoma outpatient, Brexucabtagene autoleucel; Basket (rare B-cell malignancies). It carries out the Kite External Research Program service. It works in collaboration with various institutes and companies. The company has an operational presence in the UK, Netherlands and the US. Kite Pharma is headquartered in Santa Monica, California, the US.

For a complete picture of TmCD19-IL18’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.